Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TherapeuticsMD, Inc. (TXMD)

TherapeuticsMD full-year 2025 net loss narrows to $0.7 million on higher license revenue

Positive Impact 3 of 5 earnings Written later

TherapeuticsMD reported full-year 2025 results in a press release furnished on Form 8-K. The net loss from continuing operations narrowed to $0.7 million from $2.3 million in 2024, as license revenue rose 71.6% to $3.0 million and operating expenses fell 5.9% to $7.4 million. The company said it continues to explore strategic alternatives, including a possible acquisition, merger or sale of assets, but has set no timetable and gave no assurance of a transaction.

Key points

  • Net loss from continuing operations was $(0.7) million, or $(0.06) per share, versus $(2.3) million, or $(0.20) per share, in 2024.
  • License revenue, primarily from the Mayne License Agreement, was $3.0 million, up from $1.8 million in 2024.
  • Total operating expenses were $7.4 million, down $0.5 million, mainly due to lower impairment charges.
  • Cash and cash equivalents were $7.5 million as of December 31, 2025.

The filing

CompanyTherapeuticsMD, Inc. (TXMD)
Form8-K, current report
Filed with the SECMar 30, 2026, 5:56 PM ET
Accession number0001213900-26-036519

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.